STAT+: Pharmalittle: We’re reading about a reticent FDA commish nominee, a Novo deal, and more
President Trump’s nominee to lead the FDA was grilled by senators on hot button topics like China, vaccines, and abortion access
Heidi Overton, the nominee to lead the U.S. Food and Drug Administration under President Trump, faced tough questioning by senators regarding topics such as China, vaccines, and abortion access during her committee hearing. However, she remained tight-lipped about her personal views on these pressing issues, instead focusing on existing agency guidelines and approvals for vaccines and the abortion drug mifepristone.
There was no clear indication from Overton if she would push for updates to these guidelines or approvals to align with the desires of Trump or health secretary Robert F. Kennedy Jr. Meanwhile, Novo Nordisk inked a deal with Nanexa to license and develop their PharmaShell technology, which could potentially reduce the frequency of injections required for their obesity and diabetes drugs.
The agreement covers Nanexa's technology for up to five development programs, with the goal of achieving monthly and quarterly administration frequencies.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
